Display options
Cite
Zhi T, Zhang WL, Zhang Y, et al. Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study. Bosn J Basic Med Sci. 2021;21(5):598-606doi: 10.17305/bjbms.2020.5121.
Zhi, T., Zhang, W. L., Zhang, Y., Wang, Y. Z., & Huang, D. S. (2021). Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study. Bosnian journal of basic medical sciences, 21(5), 598-606. https://doi.org/10.17305/bjbms.2020.5121
Zhi, Tian, et al. "Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study." Bosnian journal of basic medical sciences vol. 21,5 (2021): 598-606. doi: https://doi.org/10.17305/bjbms.2020.5121
Zhi T, Zhang WL, Zhang Y, Wang YZ, Huang DS. Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study. Bosn J Basic Med Sci. 2021 Oct 01;21(5):598-606. doi: 10.17305/bjbms.2020.5121. PMID: 33259778; PMCID: PMC8381201.
Copy Download .nbib Format: NLM
Share it on

Bosn J Basic Med Sci. 2021 Oct 01;21(5):598-606. doi: 10.17305/bjbms.2020.5121.

Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study.

Bosnian journal of basic medical sciences

Tian Zhi, Wei-Ling Zhang, Yi Zhang, Yi-Zhuo Wang, Dong-Sheng Huang

Affiliations

  1. Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

PMID: 33259778 PMCID: PMC8381201 DOI: 10.17305/bjbms.2020.5121

Abstract

The onset of malignant solid tumors in infants is insidious and difficult to diagnose on time. The purpose of our study is to provide a theoretical basis for clinical diagnosis by retrospective analysis of the data in the past 14 years. Here, we retrospectively collected the clinical data of infants aged 0-12 months with malignant solid tumors in Beijing Tongren Hospital Affiliated to Capital Medical University from May 2005 to May 2019. The epidemiology, clinical characteristics, treatments and prognosis were statistically analyzed. A total of 496 infants (294 males and 202 females) with malignant solid tumors were analyzed. The main period of onset was 1-11 months. The most common tumor was retinoblastoma (RB, 51.8%), followed by hepatoblastoma (HB, 26.6%), neuroblastoma (NB, 10.5%), rhabdomyosarcoma (RMS, 3.4%), malignant renal tumors (3.2%), infantile fibrosarcoma (IFS, 1.6%), malignant teratoma (1.2%), Ewing's sarcoma (ES, 0.8%), medulloblastoma (MB, 0.4%) and inflammatory myofibroblastic tumor (IMT, 0.4%). The median follow-up time was 32 months (range 2-162 months). The 1-year, 3-year, and 5-year overall survival of all patients were 97.3%, 89.2%, and 81.1%, respectively, and event-free survival was 94.7%, 84.8%, and 75.8%, respectively. In conclusion, as a special group, malignant solid tumors in infants are complex, heterogeneous, and relatively rare. The prognosis of RB, HB, NB, RMS, malignant renal tumors, IFS, malignant teratoma, ES, MB, and IMT, were excellent duo to timely diagnosis and rational treatment.

References

  1. Ann Oncol. 2015 Mar;26(3):567-72 - PubMed
  2. Lancet Oncol. 2019 Jan;20(1):e42-e53 - PubMed
  3. JCO Clin Cancer Inform. 2018 Dec;2:1-15 - PubMed
  4. Pediatr Dev Pathol. 2020 Mar-Apr;23(2):79-95 - PubMed
  5. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 - PubMed
  6. J Clin Oncol. 2017 Aug 1;35(22):2580-2587 - PubMed
  7. Neuro Oncol. 2014 Jul;16(7):975-83 - PubMed
  8. Pediatr Neonatol. 2018 Feb;59(1):65-70 - PubMed
  9. Br J Ophthalmol. 2013 Oct;97(10):1277-83 - PubMed
  10. Cir Pediatr. 2004 Jul;17(3):133-6 - PubMed
  11. J Clin Oncol. 2009 Mar 1;27(7):1014-9 - PubMed
  12. Cancers (Basel). 2019 Oct 31;11(11): - PubMed
  13. Pediatr Radiol. 2019 Oct;49(11):1516-1523 - PubMed
  14. Asian Pac J Cancer Prev. 2014;15(3):1211-7 - PubMed
  15. Eur J Cancer. 2016 Apr;57:1-9 - PubMed
  16. Acta Orthop Traumatol Turc. 2019 Nov;53(6):507-511 - PubMed
  17. CA Cancer J Clin. 2020 Jan;70(1):7-30 - PubMed
  18. Semin Oncol. 2019 Feb;46(1):48-56 - PubMed
  19. Cancer Med. 2017 Jul;6(7):1817-1826 - PubMed
  20. Ultraschall Med. 2017 Aug;38(4):443-445 - PubMed
  21. Pediatr Radiol. 2018 Apr;48(4):536-554 - PubMed
  22. Pediatr Surg Int. 2003 Sep;19(7):509-19 - PubMed
  23. Cancer Sci. 2010 Mar;101(3):787-92 - PubMed
  24. J AAPOS. 2018 Aug;22(4):276.e1-276.e7 - PubMed
  25. J Clin Oncol. 1991 Apr;9(4):581-91 - PubMed
  26. Semin Diagn Pathol. 2017 Mar;34(2):192-200 - PubMed
  27. J Pediatr Rehabil Med. 2016 May 31;9(2):117-24 - PubMed
  28. Pediatr Blood Cancer. 2016 Aug;63(8):1375-80 - PubMed
  29. Pediatr Investig. 2020 Sep 27;4(3):178-185 - PubMed
  30. Pediatr Blood Cancer. 2020 May;67(5):e28219 - PubMed
  31. Surg Endosc. 2011 May;25(5):1484-8 - PubMed
  32. Pediatr Rev. 2018 Feb;39(2):57-67 - PubMed
  33. PLoS One. 2015 Jun 25;10(6):e0130444 - PubMed
  34. Eur J Cancer. 2016 Jan;52:92-101 - PubMed
  35. Eur J Pediatr Surg. 2015 Feb;25(1):138-44 - PubMed
  36. Cancer Sci. 2016 May;107(5):690-9 - PubMed
  37. J Glob Oncol. 2018 Sep;4:1-8 - PubMed
  38. Pediatr Dev Pathol. 2004 Nov-Dec;7(6):583-94 - PubMed
  39. Pediatr Hematol Oncol. 2012 Feb;29(1):38-49 - PubMed
  40. Sci Transl Med. 2019 Jan 23;11(476): - PubMed

Publication Types